The Power List is our chance to put the pharmaceutical and drug development industry’s inspirational thought leaders, opinion shapers and unsung heroes in the spotlight. We’re relying on you to ensure that the breadth of perspectives is as wide as possible!

Business-in-Brief

Deals & acquisitions

GlaxoSmithKline is acquiring oncology company Tesaro for $5.1 billion. Tesaro is the maker of Zejula, PARP inhibitor treatment for ovarian cancer. The company has a number of other oncology assets in its pipeline.

Janssen Pharmaceuticals has entered into a collaboration with MeiraGTx to develop and commercialize gene therapies for the treatment of inherited retinal diseases. The two companies are also entering into a research collaboration to further develop AAV manufacturing technology, as well as clinical and commercial manufacturing supply agreements for the clinical and research programs.

Enjoy our FREE content!

Log in or register to read this article in full and gain access to
The Medicine Maker’s entire content archive. It’s FREE and always will be!

Or Login as a Guest or via Social Media

About the Author

Stephanie Sutton

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent seven years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.